Brokerages Set SCYNEXIS Inc (SCYX) Target Price at $10.00

Shares of SCYNEXIS Inc (NASDAQ:SCYX) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

SCYX has been the topic of several research reports. Guggenheim initiated coverage on shares of SCYNEXIS in a research note on Tuesday, October 24th. They issued a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research raised shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, October 10th. Finally, ValuEngine raised shares of SCYNEXIS from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th.

A number of hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP raised its stake in SCYNEXIS by 17.1% during the third quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock worth $499,000 after purchasing an additional 30,200 shares during the period. Vanguard Group Inc. raised its stake in SCYNEXIS by 6.0% during the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after purchasing an additional 48,978 shares during the period. Dimensional Fund Advisors LP purchased a new position in SCYNEXIS during the third quarter worth about $264,000. Finally, National Asset Management Inc. purchased a new position in SCYNEXIS during the second quarter worth about $551,000. 31.00% of the stock is currently owned by institutional investors.

SCYNEXIS (NASDAQ SCYX) remained flat at $$1.68 during trading hours on Friday. The stock had a trading volume of 87,108 shares, compared to its average volume of 236,395. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.30 and a quick ratio of 7.30. SCYNEXIS has a twelve month low of $1.52 and a twelve month high of $3.72.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.03. SCYNEXIS had a negative net margin of 8,569.46% and a negative return on equity of 64.12%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at


SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with's FREE daily email newsletter.

Leave a Reply